| __timestamp | ImmunityBio, Inc. | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 641000 | 64538000 |
| Thursday, January 1, 2015 | 236000 | 71914000 |
| Friday, January 1, 2016 | 44000 | 108973000 |
| Sunday, January 1, 2017 | 45000 | 141102000 |
| Monday, January 1, 2018 | 47000 | 251453000 |
| Tuesday, January 1, 2019 | 2202000 | 120282000 |
| Wednesday, January 1, 2020 | 605000 | 186419000 |
| Friday, January 1, 2021 | 934000 | 277133000 |
| Saturday, January 1, 2022 | 240000 | 196245000 |
| Sunday, January 1, 2023 | 622000 | 131314000 |
Unlocking the unknown
In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success and market position. Over the past decade, ImmunityBio, Inc. and Ligand Pharmaceuticals Incorporated have showcased contrasting revenue trajectories. From 2014 to 2023, Ligand Pharmaceuticals consistently outperformed, with revenues peaking at nearly $277 million in 2021, reflecting a robust growth of over 300% from 2014. In contrast, ImmunityBio's revenue journey was more volatile, with a significant spike in 2019, reaching approximately $2.2 million, a stark contrast to its earlier years. Despite this, ImmunityBio's revenue remained relatively modest compared to Ligand's. This analysis highlights the diverse strategies and market conditions influencing these biotech giants. As the industry evolves, understanding these revenue patterns provides valuable insights into their strategic directions and potential future performance.
Regeneron Pharmaceuticals, Inc. and Ligand Pharmaceuticals Incorporated: A Comprehensive Revenue Analysis
GSK plc vs ImmunityBio, Inc.: Annual Revenue Growth Compared
Takeda Pharmaceutical Company Limited vs Ligand Pharmaceuticals Incorporated: Examining Key Revenue Metrics
Genmab A/S vs ImmunityBio, Inc.: Examining Key Revenue Metrics
Walgreens Boots Alliance, Inc. or Ligand Pharmaceuticals Incorporated: Who Leads in Yearly Revenue?
Ascendis Pharma A/S and Ligand Pharmaceuticals Incorporated: A Comprehensive Revenue Analysis
Lantheus Holdings, Inc. and ImmunityBio, Inc.: A Comprehensive Revenue Analysis
Who Generates More Revenue? Corcept Therapeutics Incorporated or ImmunityBio, Inc.
Perrigo Company plc and Ligand Pharmaceuticals Incorporated: A Comprehensive Revenue Analysis
Revenue Insights: HUTCHMED (China) Limited and ImmunityBio, Inc. Performance Compared
Comparing Revenue Performance: Ligand Pharmaceuticals Incorporated or Novavax, Inc.?
Ligand Pharmaceuticals Incorporated and MiMedx Group, Inc.: A Comprehensive Revenue Analysis